Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.70 |
| ▸ | STAT3 | P40763 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.69 |
| ▸ | TYK2 | P29597 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14082180 | 0.91 | TRPV1 (0.75) | TRPV1POLBSTAT3SMN1; SMN2JAK2 | |
| SCHEMBL18573396 | 0.88 | TRPV1 (0.71) | TRPV1PTPN2PTPN1KMT2AMCHR1 | |
| SCHEMBL14082247 | 0.86 | TRPV1 (1.00) | TRPV1PTPN2PTPN1 | |
| SCHEMBL10452121 | 0.86 | TRPV1 (0.76) | TRPV1SMN1; SMN2KDM4EPTPN2PTPN1 | |
| SCHEMBL14313610 | 0.86 | TRPV1 (0.72) | TRPV1SMN1; SMN2KDM4EL3MBTL1PTPN2 | |
| SCHEMBL14082181 | 0.86 | TRPV1 (0.76) | TRPV1POLBPTPN2PTPN1KMT2A | |
| SCHEMBL18573213 | 0.85 | TRPV1 (0.71) | TRPV1PTPN2PTPN1MCHR1 | |
| SCHEMBL14082187 | 0.85 | NAMPT (0.72) | TRPV1PTPN2PTPN1NAMPT | |
| SCHEMBL3873012 | 0.83 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL29013035 | 0.83 | POLB (1.00) | TRPV1POLBSTAT3SMN1; SMN2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | TRPV1 1/4885POLB 4543/4885STAT3 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.